← boardnext 2026-09next 2027-02next 2027-12-15
SNDX
Syndax Pharmaceuticalsdistress 5/10 · elevated risk$21.46-3%today-15% from 52w high
Oncology 1
Lead: myelofibrosis (MF) · target Menin · est. market ~$4B (approx, global)
Revenue
$65M
Liquidity
$352M
Runway
1.3 yrs
Shares 1y
+3%
Price & events
+3.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-5.5%
1W
+9.4%
1M
+2.2%
3M
+6.0%
6M
+110.0%
1Y
-7.8%
2Y
+50.5%
5Y
-3.9%
All
Overview
- Market Cap
- $1.90B
- Volume
- 66.35K
- 52 Week Range
- $9.21 – $25.15
- Total Shares
- 88.61M
- Float Shares
- 79.61M
- Short %
- 25.05%
- % Held by Insiders
- 1.70%
- % Held by Institutions
- 117.24%
- RVOL
- 0.03x
- Beta
- 0.37
Pipeline stages · 3 programs
Axatilimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SNDX-5613, Chemotherapy Regimen, HiDAC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Revumenib, Intensive Chemotherapy Regimen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Axatilimab | Idiopathic Pulmonary Fibrosis | — | active not recruiting |
| 2027-02 Estimated 50% readout ~2027-03-03 | Phase 1 | SNDX-5613, Chemotherapy Regimen, HiDAC | Acute Myeloid Leukemias | — | active not recruiting |
| 2027-12-15 Estimated 50% readout ~2028-01-29 | Phase 1/2 | revumenib, cobicistat | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | — | recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 3 | Revumenib, Intensive Chemotherapy Regimen | Acute Myeloid Leukemias | — | recruiting |
| 2025-06-30 | Phase 1/2 | Revumenib, Chemotherapy | Colorectal Cancer, Solid Tumors | 42 | completed |
Catalyst news & presentations · 19
- in 2027trial initiationsecondaryPhase 1SNDX-4321 · Phase 1 trial initiation expected in 2027SEC 8-K
- expected in 2027regulatory submissionFiled (NDA/BLA)SNDX-62122 · IND submission expected in 2027SEC 8-K
- second half of 2027readoutPhase 1/2revumenib · Initial clinical data expected in H2 2027SEC 8-K
- fourth quarter of 2026trial initiationsecondaryPhase 1/2revumenib · Phase 1/2 proof-of-principle trial expected to initiate in Q4 2026SEC 8-K
- second half of 2026Guided 55%readoutaxatilimab · Topline data from MAXPIRe trial anticipatedSEC 8-K
- by the end of 2026regulatory submissionFiled (NDA/BLA)SNDX-4321 · IND submission expected by end of 2026SEC 8-K
- 2026-08-03earningsEarningsEarnings releaseyahoo
- January 2026enrollment completesecondaryPhase 2axatilimab · Complete enrollment in MAXPIRe Phase 2 trialSEC 8-K
- year-end 2025PDUFAPDUFArevumenib · Potential FDA approval for revumenib in R/R mNPM1 AMLSEC 8-K
- second half of 2025readoutPhase 1revumenib · Phase 1 data readout for revumenib + intensive chemotherapySEC 8-K
- second half of 2025trial initiationsecondaryrevumenib · Initiation of multiple trials of revumenib in combination with standard of careSEC 8-K
- 2025enrollment completesecondaryPhase 2axatilimab · Enrollment completion in MAXPIRe trialSEC 8-K
- 2Q25regulatory submissionFiled (NDA/BLA)revumenib · sNDA filing for revumenib in R/R mNPM1 AMLSEC 8-K
- first half of 2025conferencedata presentationsecondaryrevumenib · Publish and present pivotal AUGMENT-101 results at a medical conference.SEC 8-K
- first quarter of 2025trial initiationsecondaryrevumenib · Initiation of pivotal trial of revumenib in combination with venetoclax and azacitidineSEC 8-K
- 2025-03-03partnershipaxatilimab · $350 million royalty funding agreement with Royalty Pharma on U.S. net sales of NiktimvoSEC 8-K
- year-end 2024trial initiationsecondaryPhase 2revumenib · Initiate pivotal combination trial with venetoclax/azacitidine.SEC 8-K
- Q4 2024PDUFAPDUFArevumenib · Anticipated FDA approval for R/R KMT2Ar acute leukemias.SEC 8-K
- December 2024conferencedata presentationsecondaryrevumenib · Present data at ASH Annual Meeting.SEC 8-K
Approved drugs (1)
- REVUFORJREVUMENIB CITRATE2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $39 (+82% upside) · 12 analysts
- 2026-07-15HC Wainwright & Co.Buy
- 2026-06-12HC Wainwright & Co.Buy
- 2026-05-22HC Wainwright & Co.Buy
- 2026-05-13UBSBuy
- 2026-05-01BarclaysOverweight
- 2026-04-01Goldman SachsBuy
Recent news
- 2026-07-21Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
- 2026-07-19Syndax Pharmaceuticals (SNDX) FDA Announcement Summary - Quartr
- 2026-07-19Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
- 2026-07-18Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-17Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - Sahm
- 2026-07-17SNDX Stock Price, Quote & Chart - ChartMill
- 2026-07-15Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.